Runsheng Wang is a Rheumatology/Immunology physician. OpenAlex indexes 84 publications with 7,628 citations (h-index 24); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2333 Morris Ave Ste B111
Union, NJ 070835716
Telephone
908-977-1677Provider last certified this registry record 2 Nov 2023.
Clinical trials
- Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis
Sponsor: Columbia University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20221 payment
- Novartis Pharmaceuticals CorporationProgram year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
36.3%Folate Analog Metabolic Inhibitor13.9%Methotrexate100%Part D≥29 patientsAntirheumatic Agent4.5%Leflunomide100%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
23.6%Corticosteroid23.6%Prednisone100%Part D≥49 patientsMusculoskeletal
13.5%Xanthine oxidase inhibitor5.9%Allopurinol100%Part D≥13 patientsNonsteroidal Anti-inflammatory Drug5.5%Diclofenac Sodium100%Part D≥26 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- CyTOF-based profiling of circulating tumor cells predicts aggressiveness and therapy response in SCLC liquid biopsies at a personalized level
bioRxiv (Cold Spring Harbor Laboratory)
2025 - Comparison of inebilizumab or rituximab in addition to glucocorticoid therapy for neuromyelitis optica spectrum disorders
International Journal of Ophthalmology
2024 - Intermittent hypoxic pretreatment exacerbates house dust mite‐induced asthma airway inflammation
Immunity Inflammation and Disease
2024
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”